Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nachtnebel A. Pomalidomide (Pomalyst®) for the treatment of refractory multiple myeloma or relapsed and refractory multiple myeloma. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). Horizon Scanning in Oncology Nr. 39. 2013 Indexing Status Subject indexing assigned by CRD MeSH Humans; Multiple Myeloma; Pyrazines; Thalidomide Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: anna.nachtnebel@hta.lbg.ac.at AccessionNumber 32013000926 Date abstract record published 11/12/2013 |